Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248764 | 0.97 | MEN1 (0.46) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4252966 | 0.96 | MEN1 (0.48) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4244880 | 0.95 | MAPK14 (0.42) | MEN1KMT2ARAB9ANPC1HPGD | |
| SCHEMBL4251504 | 0.90 | CA12 (0.42) | MEN1KMT2ARAB9AGRM5SMN1; SMN2 | |
| SCHEMBL4246203 | 0.89 | TAS1R3 (0.48) | KMT2ARAB9ANPC1GRM5CYP2C9 | |
| SCHEMBL4241570 | 0.87 | MEN1 (0.51) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4252793 | 0.85 | CNR1 (0.42) | — | |
| SCHEMBL4242303 | 0.85 | TAS1R3 (0.42) | CYP2C9MAPK14 | |
| SCHEMBL4242205 | 0.84 | TAS1R3 (0.55) | — | |
| SCHEMBL4249996 | 0.84 | MAPK1 (0.53) | MEN1KMT2AMAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902400-B2 | N-(1,1-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; N-(2,2-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; controlling plant diseases | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7902400-B2 | N-(1,1-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; N-(2,2-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; controlling plant diseases | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7902400-B2 | N-(1,1-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; N-(2,2-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; controlling plant diseases | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20090131531-A1 | Amide Compounds and their Use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131531-A1 | Amide Compounds and their Use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131531-A1 | Amide Compounds and their Use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1940780-A1 | AMIDE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL CO., LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007049728-A1 | AMIDE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131531-A1 | Amide Compounds and their Use | NAT1, ACAT2, NAAA | MEN1 3713/4885KMT2A 909/4885RAB9A 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.